262 results about "Protamine" patented technology

The present invention relates to insulin crystals formed from zinc, protamine, a hexamer-stabilizing compound, and a polypeptide selected from the group consisting of insulin, an insulin analog, and a derivatized insulin. The crystals are suitable for administering to a patient for control of blood glucose levels. The crystals have been derived from the neutral protamine Hagedorn (NPH) form in a process utilizing precisely determined protamine concentrations and fortification of NPH crystals formed at a first lower concentration of protamine to achieve a second higher concentration of protamine.

The present invention relates to a process for forming non-adsorbed insulin crystals from zinc, protamine, a hexamer-stabilizing compound, and a polypeptide selected from the group consisting of insulin, an insulin analog, a derivatized insulin, and a derivatized insulin analog. The crystals are suitable for administering to a patient for control of blood glucose levels. The crystals are formed in a process utilizing precisely determined protamine concentrations.

The present invention provides antigen delivery compositions and methods of using same to prevent or to treat cancers and other infectious diseases. More particularly, the present invention provides a lipid-protamine-DNA (LPD) vaccine delivery system and methods of using such LPD vaccine delivery system for the prevention and treatment of cancer and other infectious diseases.

A method and system for use in the course of extracorporeal blood flow, e.g., cardiopulmonary bypass, dialysis, and angioplasty procedures, in order to reduce or minimize inflammation, excessive bleeding, and other undesirable side effects. The system can include one or more automated blood parameter sensor modules and one or more blood parameter regulating modules. The system is particularly well suited to monitor and/or regulate blood parameters that include blood analytes (e.g., biomolecules, drugs or metabolites) as well as blood functions (e.g., clotting time, fibrinolytic activity, immune response). The system is particularly well suited for use in the management of clotting (e.g., heparing/protamine) and bleeding (e.g., aprotinin).

Disclosed is a safe and non-toxic prophylactic or therapeutic composition for diabetes or obesity. The prophylactic or therapeutic composition for diabetes or obesity comprises as an active ingredient, a calcium receptor activator such as γ-Glu-X-Gly, wherein X represents an amino acid or an amino acid derivative; γ-Glu-Val-Y, wherein Y represents an amino acid or an amino acid derivative; γ-Glu-Ala; γ-Glu-Gly; γ-Glu-Cys; γ-Glu-Met; γ-Glu-Thr; γ-Glu-Val; γ-Glu-Orn; Asp-Gly; Cys-Gly; Cys-Met; Glu-Cys; Gly-Cys; Leu-Asp; γ-Glu-Met(O); γ-Glu-γ-Glu-Val; γ-Glu-Val-NH₂; γ-Glu-Val-ol; γ-Glu-Ser; γ-Glu-Tau; γ-Glu-Cys(S-Me)(O); γ-Glu-Leu; γ-Glu-Ile; γ-Glu-t-Leu; γ-Glu-Cys(S-Me); cinacalcet; a cinacalcet analogue compound and protamine.

The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of protamine to result in protamine proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.

The invention relates to an aptamer-based targeted delivery microRNA nanometer carrier as well as a preparation method and application thereof. A targeting molecule is a sulfydryl-modified MUC-1molecule, and can be combined with cancer-inhibiting microRNA-34a, so that a MicroRNA-nanodiamond-protamine complex (MNPs) becomes AMNPs with an active targeting function; through electrostatic interaction, a negatively-charged aptamer-microRNA (Apt-miR) chimera is adsorbed to a cationic protamine-nanodiamond carrier to form a trinary compound carrier. The therapeutic effect of a nanotransport system on a non-small cell lung cancer is researched; the Apt-miR chimera is low in immunogenicity; the modified MUC-1 aptamer has high chemical stability in vivo, and can be chemically synthesized easily; in order to improve the transfection efficiency, a protamine-modified nanodiamond material (NPs) is used for helping miRNA to increase accumulation in a tumor part through permeability and retention enhancing effects.

Provided are bioactive, low-toxicity protamine fragments, compositions, combinations, kits and methods of using these components in a variety of embodiments, including neutralizing heparin and reducing post-operative bleeding. Improved protamine fragment-insulin solutions and methods for treating diabetes are also provided.

The invention relates to preparation of protamine gold nanoclusters and application in analogue enzyme color comparison and fluorescence detection. The protamine gold nanoclusters not only have activity of horseradish peroxidase and oxidase, but also have fluorescent characteristic. Hereby, a protamine gold nanocluster analogue enzyme visual color comparator and a fluorescence sensor are established respectively and are used for detecting heavy metal ions. The protamine gold nanoclusters are prepared simply and conveniently, are low in cost, and have excellent fluorescence stability and chemical stability, and the shortcomings that fluorescence of traditional dyestuff is short in service life, photobleaching occurs easily and the like can be overcome; a fluorescence method is high in sensitivity and good in stability, and expensive instruments are not required; and analogue enzyme catalytic color comparison is sensitive and environment-friendly, and can be used for field real-time monitoring. The protamine gold nanoclusters are expected to be expanded and applied to detection and analysis of related substances in the fields of environment and biomedicines and disease markers, and have wide application prospect.

The invention relates to detection of heparins, in particular to a quick, accurate and sensitive method for detecting heparins. The method comprises the following steps of: testing potential changes caused by adding of heparins of different concentrations by using a potential tester according to specific combination of protamine in a polymer sensitive film phase and heparins in a water phase; drawing a standard work curve according to an initial potential change rate; and obtaining the concentration of heparins in an unknown sample in reference to the standard work curve. In the invention, protamine is added into a polymer film, so that the protamine is not required to be added manually; and an electrode can be directly applied to sample detection without activating, so that the method has the advantages of easiness and convenience for operating, short detection time, low operating cost, suitability for field detection, and the like.

The invention belongs to the technical field of separation and purification of bio-active substances, more particularly relates to a method for directly separating and purifying the protamine from crude protamine extract with a reverse micelle method. The invention aims at solving the problems of complex process, multiple steps and long cycle of present protamine purification. The invention directly separates, purifies the protamine from the crude protamine extract by adopting the reverse micelle solution which consists of a surfactant and an organic solvent and can realize the high-efficient extraction and back extraction of the protamine by adjusting the conditions of extraction processes such as pH of water phases, ionic strength, phase ratio, contact time of two phases; the highest enzyme recovery rate can reach more than 96 percent and the purification factor reaches more than 2.1. The process has the effects of both concentration and decoloration. In addition, the separation and purification of the protamine with the reverse protamine technology have the advantages of short cycle, convenient continuous operation and being easily amplified.

The invention relates to an isulin analogue having quick response and stability under acidic condition, and a medicinal composition and a medicinal preparation thereof. Asparagine (Asn) at the A 21 position of the chain A of the isulin analogue is mutated into glycine (Gly), the isulin analogue can be mixed with a long-acting isulin analogue such as insulin glargine to form a premixed preparationwith two functions of quick-acting sugar reduction and stable long-acting sugar reduction, and the problems that the conventional natural insulin (of pigs, cows and human) and quick-acting isulin analogues are unstable in the acidic environment, and the conventional isulin premixed preparation is not clarified and needed to be introduced with a foreign protein (such as protamine) serving as a slow release preparation so as to easily cause immune reaction, and is needed to be injected twice each day, namely in the morning and evening are solved, so that the safety of the preparation is higher.

The invention discloses an oral insulin complexing preparation, which is characterized by the following: allocating 1-15% insulin raw material, 50-97% stable protecting agent, 1-15% carrying medicine carrier, 1-20% absorption promoting agent; setting the stable protecting agent as one or several of carbowax and casein, protamine, albumin and protease inhibitor; setting the carrying medicine carrier as calcium phosphate salt; setting the absorption promoting agent as one or several of salicylic acid, cholate and fatty acid; setting the insulin raw material as human retooling insulin or human retooling insulin chemical trimmed by single methoxy carbowax derivant. This invention also relates to a preparing method of oral insulin complexing preparation. This invention can increase biostability of human retooling insulin and can resist degradation of gastrointestinal tract enzyme.

The invention belongs to the technical field of food processing and particularly relates to a compound food preservative. The compound food preservative comprises the following components in parts by mass: 3-9 parts of protamine, 11-14 parts of propolis, 10-16 parts of a lotus leaf extract, 12-16 parts of chitosan, 4-10 parts of tea polyphenol, and 50-70 parts of water. The components, such as the protamine, the propolis, the lotus leaf extract, the chitosan, the tea polyphenol, the water, essential oil, D-sodium erythorbate and allicin, adopted by the compound food preservative can be widely applied to food and can play a role in keeping freshness and preventing corrosion; as the natural components, such as the protamine, the propolis and the lotus leaf extract, are taken as main components of the compound food preservative and include extracts of natural plants and natural animal sources, the health of consumers cannot be damaged seriously even though the consumers eat a large quantity of preservative, and the natural components have excellent preservative effect.

The invention belongs to the technical field of food processing, and particularly relates to safe food preservative. The safe food preservative comprises, by mass, 2-7 parts of gingko leaf extractives, 4-9 parts of lysozyme, 12-15 parts of chitosan, 3-7 parts of spice extractives, 4-10 parts of protamines and 80-100 parts of water. According to the safe food preservative, the main inhibiting objects are pseudomonades, micrococcus, bacilli, enterobacteriaceae, vibrios, halobacterium, mycete and the like, and the application range is wide in beverages, seasoning, cooked wheaten food, cakes, sausages, canned fruit, various melons and fruits, vegetables and the like.

Embodiments of the invention include methods and compositions including viral composition that have high transduction efficiencies in vivo, in vitro and ex vivo. The viral composition include a viral vector and a protamine molecule, wherein the viral vector includes a polynucleotide encoding a tumor suppressor gene. The methods of the invention include administering the viral composition to a patient or subject for treatment of disease, in particular cancer, that is characterized by a reduced vector-induced production of neutralizing antibodies and a decreased vector-induced toxicity as compared to delivery of viral vectors alone.

Methods and devices for point of care determination of heparin concentration in blood are described. Cartridges including protamine ion sensitive electrodes (ISEs) and reference electrodes and systems for automatically determining heparin concentration in the cartridges are provided. Some systems add blood to a protamine bolus sufficient to bind all heparin, leaving excess protamine. The excess protamine concentration can be determined by measuring the initial slope of the electrode potential rate of change, and comparing the slope to known protamine concentration slope values In some cartridges, an oscillating pressure source moves the blood-protamine mixture back and forth across the protamine ISE. Some systems also use a second blood sample having the heparin removed or degraded to create a blank reference sample. Protamine ISEs can include polyurethane polymer, DNNS ionophore, and NPOE plasticizer. The polyurethane may include hard segments and soft segments, where both hard and soft segments may include cyclic and straight chain aliphatic moieties having essentially no ester or ether groups. Some hard segments may include methylene diphenyl groups. Some reference electrodes have the same polymer, plasticizer, and ionophore as the measurement electrode, but with a different concentration of ionophore.

The invention relates to a silicon oxide and protamine microcapsule and a preparation method thereof. The silicon oxide and protamine microcapsule is prepared by using a calcium carbonate particulate as a template and sodium silicate and protamine as raw materials, wherein the mass ration of the sodium silicate to the protamine is 1:1-7:1. The preparation method comprises the following steps: firstly preparing the calcium carbonate particulate with negative charges as the template; interacting the protamine with positive charges and the calcium carbonate particulate with negative charges and alternately absorbing to the template; inducing the forming of silicon oxide by using the biomineralizing function of the protamine when three to five double-layers are generated on the template; removing the inner core of the calcium carbonate by EDTA-2Na. The invention is gentle in reaction conditions during the preparation of the silicon oxide and protamine microcapsule. The prepared silicon oxide and protamine microcapsule has the advantages of gentle reaction condition, size controllability, good stability, and excellent repeatability.

The invention discloses soft-granule pseudosciaena crocea juvenile compound feed which comprises fish meal, pre-gelatinized starch, extruded soybean, fermented soybean meal, corn protamine, fish oil, beer yeast, mineral, monocalcium phosphate, choline chloride, vitamin complex and the like. Compared with the traditional feed, the pseudosciaena crocea juvenile compound feed disclosed by the invention has the advantages of comprehensive nutrition, little pollution to culture water and wide source of raw materials; and compared with the existing extruded granulated feed, the soft-granule compound feed has the advantages of high feed conversion rate, high digestion utilization rate and the like, and is convenient to produce and green and pollution-free.

The invention discloses a protamine DNA-NA extract, a protamine protein extract and a preparation method thereof. The method is as follows: (1) take the fish testis, add water to wash it, drain the water, and obtain the raw material of the fish testis; (2) add 1 to 10 times the volume of water, and at a temperature of 37 to 58 ° C, add 0.1 to 1.2%, enzymatic hydrolysis for 30 to 300 minutes; (3) Concentrate the filtrate to 30 to 80%; (4) Adjust the pH to 6.0 to 8.0 and put it on a cation exchange resin column, collect the effluent, and combine the combined effluent and eluate (5) Use 1-5% sodium chloride solution to continue eluting the cation exchange resin until the effluent has no protein, and collect the eluate. The protamine extract and protamine DNA-NA extract have high yield and purity, can be obtained simultaneously, and do not use polluting and toxic substances.

The invention discloses soft-granule pseudosciaena crocea medium compound feed which comprises fish meal, pre-gelatinized starch, extruded soybean, fermented soybean meal, corn protamine, fish oil, beer yeast, mineral, monocalcium phosphate, choline chloride, vitamin complex and the like. Compared with the traditional feed, the soft-granule pseudosciaena crocea medium compound feed disclosed by the invention has the advantages of comprehensive nutrition, little pollution to culture water and wide source of raw materials; and compared with the existing extruded granulated feed, the soft-granule compound feed has the advantages of high feed conversion rate, high digestion utilization rate and the like, and is convenient to produce and green and pollution-free.